Review Article

Yang Y. · Sun J. · Wu M. · Lau W.Y. · Zheng S. · Wang X.-H. · Chen X. · Fan J. · Dong J. · Cai J. · Chen M. · Chen Y. · Cheng Z. · Dai C. · Shan J. · Du C.-Y. · Fang C. · Hu H. · Ji Z. · Jia W. · Li G. · Li J. · Li J. · Liu C. · Liu F. · Ma Y. · Mao Y. · Niu Z. · Shen J. · Shi J. · Shi X. · Song W. · Sun H.-C. · Tan G. · Tao R. · Wang X. · Wen T. · Wu L. · Xia J. · Xiang B.-D. · Yan M. · Ying M. · Zhang L. · Zhang X. · Zeng Z.C. · Zhang Y. · Zhang Z. · Zhou J. · Zhou C. · Zhou J. · Zhou L. · Zhou X. · Zhu J. · Zhu Z. · Zhang Q. · Li Q. · Cheng S. · On behalf of Chinese Association of Liver Cancer and Chinese Medical Doctor Association
Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are firstly diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the “Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)” based on current clinical studies and clinical medication experience for reference in China. Key messages: The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients and potential population for immunotherapy.

The Author(s). Published by S. Karger AG, Basel

Article / Publication Details Open Access License / Drug Dosage / Disclaimer This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.